Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational Study Into the Usage and Efficacy of Crestor 5mg as a Start Dosage in Achieving the LDL-C Target Level in Both Statin-naive and Treated Primary and Secondary Prevention Patients With a High Risk of a Cardiovascular Event.

NCT00347217 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00347217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00347217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational Study Into the Usage and Efficacy of Crestor 5mg as a Start Dosage in Achieving the LDL-C Target Level in Both Statin-naive and Treated Primary and Secondary Prevention Patients With a High Risk of a Cardiovascular Event.
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
February 28, 2006
Completion date
January 31, 2009
Enrollment
3,840 (estimated)
Sites
215

Conditions

As the registry lists them; a condition with its own page is linked.

hypercholesteremia